Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise.
The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge.
This week we sit down with Jay Rosenthal
Limbo as a moat
EU GMP advantage
Regulation's hidden winners
Chapters
00:00 Federal limbo becomes the business model
02:17 The reform everyone agrees on
03:28 Capital markets and the bigger pond
05:35 Six hundred brands and no patience
06:55 Why Rochester can move New York
09:48 Strong operators become obvious
13:40 The cost of crossing state lines
16:28 Aurora Curaleaf and scarce EU GMP assets
20:26 The Canadian future that did not arrive
22:00 What mature industry compliance could bring
24:35 Cultivated's nonsecret sauce
31:41 Cannabis stigma still follows the operator
32:28 Why Cultivated launched membership
40:23 Quality media has a real cost
41:18 California and New York regulators share a market
44:02 Policy goals that fight each other
49:06 Competition cooperation and price compression
Podden och tillhörande omslagsbild på den här sidan tillhör
Bryan Fields. Innehållet i podden är skapat av Bryan Fields och inte av,
eller tillsammans med, Poddtoppen.
